Screener
HealthEquity HQY Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by HealthEquity in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: HealthEquity’s 10-Q, filed May 28, 2026.
- Filed
- May 28, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0001428336-26-000028
| (in thousands) | Three months ended April 30, 2026 | Three months ended April 30, 2025 |
|---|---|---|
| Repurchases of common stock | (123,314) | (59,065) |
| Principal payments on long-term debt | (15,000) | — |
| Settlement of client-held funds obligation, net | 716 | 1,451 |
| Proceeds from exercise of common stock options | 418 | 965 |
| Net cash used in financing activities | (137,180) | (56,649) |
| Decrease in cash and cash equivalents | (53,558) | (8,054) |
| Beginning cash and cash equivalents | 318,927 | 295,948 |
| Ending cash and cash equivalents | $265,369 | $287,894 |
Item 1. Financial statements
FAQ
- What is HealthEquity's cash & equivalents?
- HealthEquity (HQY) reported cash & equivalents of $265.37M in Q1 2026.
- How has HealthEquity's cash & equivalents changed year-over-year?
- HealthEquity's cash & equivalents decreased by 7.8% year-over-year, from $287.89M to $265.37M.
- What is the long-term trend for HealthEquity's cash & equivalents?
- Over 5 years (2021 to 2026), HealthEquity's cash & equivalents has grown at a -0.6% compound annual growth rate (CAGR), from $328.8M to $318.93M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about HealthEquity's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude